Treatment of Bordetella parapertussis Infection
Treat Bordetella parapertussis infection with the same macrolide antibiotics used for Bordetella pertussis, following CDC pertussis treatment guidelines: azithromycin is the first-line agent for all ages, with age-specific dosing. 1
First-Line Treatment: Azithromycin
The CDC pertussis guidelines explicitly apply to both B. pertussis and B. parapertussis infections, as these organisms share similar antimicrobial susceptibility patterns 2, 3. Azithromycin is preferred across all age groups due to superior safety profile, convenient dosing, and excellent in vitro activity 1, 2.
Age-Specific Azithromycin Dosing:
- Infants <6 months: 10 mg/kg per day for 5 days 1
- Infants and children ≥6 months: 10 mg/kg (maximum 500 mg) on day 1, then 5 mg/kg per day (maximum 250 mg) on days 2-5 1
- Adults: 500 mg on day 1, then 250 mg per day on days 2-5 1
Critical timing consideration: Prompt treatment initiated within 0-6 days of cough onset significantly shortens illness duration (median 10 vs 19 days in untreated patients) 4. This underscores the importance of early diagnosis and treatment initiation.
Alternative Agents
Erythromycin (Second-Line)
Use when azithromycin is unavailable, though it has more gastrointestinal side effects and requires longer treatment duration 1:
- Infants <1 month: NOT preferred due to infantile hypertrophic pyloric stenosis (IHPS) risk; use azithromycin instead 1
- Infants >1 month and children: 40-50 mg/kg per day (maximum 2 g/day) in 4 divided doses for 14 days 1
- Adults: 2 g per day in 4 divided doses for 14 days 1
Important caveat: The 14-day course is necessary because relapses have been reported with shorter 7-10 day regimens 1.
TMP-SMZ (For Macrolide Intolerance)
Reserved for patients ≥2 months who cannot tolerate macrolides or have macrolide-resistant infection (rare) 1:
- Infants <2 months: CONTRAINDICATED (kernicterus risk) 1
- Children ≥2 months: TMP 8 mg/kg/day + SMX 40 mg/kg/day in 2 divided doses for 14 days 1
- Adults: TMP 320 mg/day + SMX 1,600 mg/day in 2 divided doses for 14 days 1
Household Contact Prophylaxis
Prompt azithromycin prophylaxis of household contacts prevents secondary illnesses (relative risk 0.16 for developing cough illness when prophylaxis given promptly) 4. Use the same age-specific azithromycin dosing regimen as for treatment.
This is particularly important because B. parapertussis causes pertussis-like illness that is clinically indistinguishable from B. pertussis infection 4, 5, and household transmission is common.
Key Clinical Pitfalls
Misdiagnosis risk: B. parapertussis causes pertussis-like symptoms and will be misclassified as pertussis if specific B. parapertussis testing is not performed 4. Ensure your laboratory testing differentiates between the two organisms.
Neonatal IHPS risk: Never use erythromycin as first-line in infants <1 month; azithromycin has not been associated with IHPS 1. If erythromycin must be used in this age group, monitor closely for pyloric stenosis symptoms.
Ineffective antibiotics: Do NOT use ampicillin, amoxicillin, or cephalosporins—these have been proven ineffective at clearing Bordetella from the nasopharynx despite in vitro activity 1.
Drug interactions: Azithromycin should not be taken simultaneously with aluminum- or magnesium-containing antacids (reduces absorption). Monitor patients on digoxin, triazolam, or ergot alkaloids 1.
Antimicrobial Susceptibility Context
Research confirms that B. parapertussis maintains excellent susceptibility to macrolides, with azithromycin showing the highest activity (MIC90 = 0.06 mg/L) 2. Susceptibility patterns have remained stable over decades 2, though B. parapertussis typically requires 2-16 fold higher concentrations than B. pertussis for some agents 3. Macrolide resistance remains rare 1.